US Markets
Home›US Markets›M&A & Deals›AstraZeneca weighs a possible merger with Bristol Myer…
AstraZeneca weighs a possible merger with Bristol Myers Squibb
The talks, described by the Financial Times, would involve a deal valued at about $400 billion.
AstraZeneca is reported to be considering a merger with U.S. rival Bristol Myers Squibb, according to coverage cited by CNBC.
The Financial Times has said the potential combination would be on a mega scale, with a suggested value around $400 billion.
Both outlets frame the development as discussions around a possible merger, with no final terms or outcome reported in the available summary.
← Newer storySenate floor schedule omits CLARITY Act as clock nears Aug. recessOlder story →UK PM Burnham backs written constitution as devolution push grows